Drug Trial Radar · NCT02559310
Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia
Last checked: Nov 19, 2026Latest source record: Oct 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
551
Actual
Start
Sep 2015
Primary completion
Apr 2017
Study completion May 2017
Sponsor
- Lead sponsor
- Nabriva Therapeutics AGIndustry
- Sponsor type
- Industry
- First posted
- Sep 24, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the safety and efficacy of lefamulin, a pleuromutilin, for the treatment of adults with moderate to severe community-acquired bacterial pneumonia.
Conditions
- Community Acquired Pneumonia
Interventions
lefamulinDrug
antibacterial agent
MoxifloxacinDrug
antibacterial agent
LinezolidDrug
antibacterial agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Early Clinical Response (ECR)Time frame: ECR was assessed 96 +/- 24 hours after the first dose of study drug.
Locations
99 sites in 18 countries. Site status is shown where the registry gives one.
Site 1006
Hazard, Kentucky
Site 1008
Shreveport, Louisiana
Site 1005
Minneapolis, Minnesota
Site 1001
Butte, Montana
Site 1009
Akron, Ohio
Site 1002
Dayton, Ohio
Site 1004
Splendora, Texas
Site 3003
Córdoba, Argentina
Site 3007
Córdoba, Argentina
Site 3001
Córdoba, Argentina
Site 3004
Córdoba, Argentina
Site 3005
La Plata, Buenos Aires, Argentina
Site 3006
Rosario, Santa Fe Province, Argentina
Site 4003
Mostar, Bosnia and Herzegovina
Site 4001
Tuzla, Bosnia and Herzegovina
Site 4004
Zenica, Bosnia and Herzegovina
Site 3104
Belo Horizonte, Minas Gerais, Brazil
Site 3102
Passo Fundo, Rio Grande Do Sol, Brazil
Site 3103
Campinas, São Paulo, Brazil
Site 3101
Sao Paulo Do Rio Preto, São Paulo, Brazil
Site 4105
Gabrovo, Bulgaria
Site 4107
Lovech, Bulgaria
Site 4112
Pernik, Bulgaria
Site 4103
Rousse, Bulgaria
Site 4108
Smolyan, Bulgaria
Site 4102
Sofia, Bulgaria
Site 4101
Sofia, Bulgaria
Site 4106
Sofia, Bulgaria
Site 4110
Sofia, Bulgaria
Site 4111
Sofia, Bulgaria
Site 4104
Veliko Tarnovo, Bulgaria
Site 4109
Vidin, Bulgaria
Site 4206
Tbilisi, Georgia
Site 4204
Tbilisi, Georgia
Site 4205
Tbilisi, Georgia
Site 4201
Tbilisi, Georgia
Site 4202
Tbilisi, Georgia
Site 4305
Budapest, Hungary
Site 4306
Csorna, Hungary
Site 4304
Debrecen, Hungary
Showing 40 of 99 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.